Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 26Lymphoma, Non-Hodgkin 22Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 14Lymphoma, Follicular 13Recurrence 12Waldenstrom Macroglobulinemia 9Neoplasms 8Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphoid 6Leukemia, B-Cell 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Myeloid, Acute 3Leukemia 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Neoplasms 3Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × ibrutinib × Clear all
NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡